Abstract 872P
Background
Intratumor heterogeneity (ITH) is a major cause of treatment failure in cancer. Data on ITH are scarce in head and neck squamous cell carcinoma (HNSCC). We evaluated pathological ITH (pITH) and assessed its prognostic value, along with classical prognostic parameters.
Methods
HNSCC patients treated with curative-intent primary surgery from SCANDARE (NCT03017573) were included. A pITH score (I, II, III-low and III-high) was assessed on biopsies, according to the relative contribution of poorly- and well-differentiated tumor contingents. Univariate and multivariate prognostic Cox models of recurrence-free survival (RFS) were made on pITH score and clinical (age, sex, smoking history, alcohol consumption, AJCC T- and N-stage, HPV status), pathological (differentiation, tumor-infiltrating lymphocytes [TILs], and PD-L1 combined positive score (CPS) features. We tested associations between pITH score and these parameters.
Results
A total of 88 patients were included. Most frequently tumor locations were oral cavity (51%). Most patients had low T-stage (T1-2, 59%) and HPV-negative tumor (74%). Ten patients (11%) had a I/II ITH score, 49 (56%) a III-low and 29 (33%) a III-high. Median follow-up was 17 months and median RFS was 18 months (95% CI, 14-40). In univariate analysis, the pITH score did not correlate with RFS (P = 0.6). T-stage, N-stage and TILs enrichment were associated with RFS (T3-4 vs T1-2, HR = 2.7, 95% CI, 1.4-5.3; N1-2 vs N0, HR = 1.9, 95% CI, 1.0-3.7; TILs ≥10% vs TILs <10%, HR = 0.3, 95% CI, 0.1-0.8). We found that low T-stage (T1-2) and high TILs enrichment (TILs ≥10%) were associated with a reduced risk of relapse in multivariate analysis (HR = 0.4, 95% CI, 0.2-0.9 and HR = 0.2, 95% CI, 0.04-0.5, respectively). In comparison with non-smokers, smokers had a higher proportion of tumors with I-II ITH score (19% vs 3%) and a lower proportion of tumors with III-low ITH score (48% vs 65%, adjusted P = 0.05).
Conclusions
We reported an association between pITH score and smoking history. pITH score was not found to be prognostic whereas TILs enrichment ≥10% was associated with a favorable prognosis in patients with HNSCC treated with upfront surgery. This finding is to be confirmed in an independent population.
Clinical trial identification
NCT03017573 SCANDARE.
Editorial acknowledgement
Legal entity responsible for the study
Pr Christophe Le Tourneau.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
818TiP - REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)
Presenter: R. Wendel Naumann
Session: Poster session 12
819TiP - FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours
Presenter: Funda Meric-Bernstam
Session: Poster session 12
820TiP - A randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P trial)
Presenter: Hyun-woong Cho
Session: Poster session 12
821TiP - Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Presenter: Geoffrey Shapiro
Session: Poster session 12
862P - Clinical utility of circulating tumor HPV16 DNA detection in plasma from oropharyngeal squamous cell carcinoma patients
Presenter: Ana Carolina de Carvalho
Session: Poster session 12
863P - Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
Presenter: Danilo Galizia
Session: Poster session 12
864P - Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Grégoire Marret
Session: Poster session 12
865P - Molecular analysis of surgical margins in early oral carcinomas (OSCC)
Presenter: Antoine Moya-Plana
Session: Poster session 12
866P - Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer
Presenter: Geoffrey Liu
Session: Poster session 12
867P - Predicting HPV-association using regular H&E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
Presenter: Jens Peter Klussmann
Session: Poster session 12